Leiden, The Netherlands

Developing innovative therapeutics for cancer

BIMINI Biotech is a Leiden-based start-up that is developing innovative first-in-class therapeutics for oncology by uniquely targeting the Wiskott-Aldrich-Syndrome protein


Targeting the Wiskott-Aldrich-Syndrome Protein

BIMINI’s approach is based on proprietary technology that targets the Wiskott-Aldrich-Syndrome Protein (WASp), an actin nucleation related protein expressed exclusively in hematopoietic cells. WASP modulation has shown to deliver a potent anti-cancer effect.

We have a proprietary portfolio of small molecule WASP modulators (agonists and antagonists), including a proprietory WASP agonist (BM-011 – licensed from the Institute of Oncology Research in Switzerland) that is currently in the pre-clinical stage and is demonstrating potent activity in various lymphomas.

Our Team

BIMINI Biotech combines young ambitious entrepreneurs with scientific key-opinion-leaders and seasoned business experts

Digvijay Gahtory PhD


Maurits van den Nieuwboer

Maurits van den Nieuwboer PhD


Stephen Croke

Stephen Croke PhD

Lead R&D Scientist

Prof. Francesco Bertoni PhD

Scientific advisor

Prof. Nathaniel Martin

Prof. Nathaniel Martin

Advisor Chemistry

Henk Viëtor PhD, MD

Advisor BD

Prof. Marc Peeters PhD

Advisor Clinical

Peter Maas

Advisor MedChem

Carine van den Brink

Advisor Legal

Prof. Ger Strous PhD

Advisor Cell Biology

Ernst Elhorst

Advisor Licensing

Latest News

Keep up to date with the latests progression and achievement of BIMINI Biotech.

BIMINI welcomes Prof. Nathaniel Martin as advisor chemistry

BIMINI Biotech is happy to have Prof. Nathaniel Martin join the team as an advisor on chemistry, supporting the lead optimization. Prof. Martin is  Professor of Biological Chemistry Institute of[…]

Read more

BIMINI Biotech’s MIT Feasibility grant AUTO-WASP awarded

BIMINI Biotech has received a MIT feasibility grant (€20.000) for the AUTO-WASP project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In[…]

Read more
Seed funding

BIMINI Biotech closes new seed round with Libertatis Ergo Holding for the development of first-in-class therapeutics

Leiden, 29 June 2023 – BIMINI Biotech, an innovative Leiden-based therapeutics start-up that develops novel therapeutics for hematological cancers, raised an additional investment of €250,000 from lead investor Libertatis Ergo[…]

Read more

Contact us

Please contact us at info@biminibiotech.nl

De contactformulier wordt hier getoond. Voor het activeren moet je de parameter ”shortcode contactformulier” instellen van het Aanpassing menu.